New drug cocktail aims to fight recurrent head and neck cancer

NCT ID NCT06668961

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase II trial is testing whether two experimental drugs (SI-B001 and SI-B003) plus standard chemotherapy can help people with head and neck cancer that has come back or spread. About 60 adults aged 18 to 75 will receive the combination as their first treatment. The main goal is to see how many patients' tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SI-B001 and SI-B003 (investigational drugs) combined with platinum-based chemotherapy
What this could lead to: If successful, this combination could offer a new first-line treatment option for people with recurrent or metastatic head and neck cancer, potentially shrinking tumors and delaying disease progression.
What could go wrong: This is an early Phase II trial with only 60 participants, so results may not apply to everyone. The drugs are experimental, and side effects from the combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.